Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
SCB-1019 by Clover Biopharmaceuticals for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
SCB-1019 is under clinical development by Clover Biopharmaceuticals and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections. According...